missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Tocris Bioscience™ AZD 4547
Potent and selective FGFR inhibitor
247.00€ - 958.00€
Spécification
| Nom chimique ou matériau | rel-N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-[(3R,5S)-3,5-dimethyl-1-piperazinyl]benzamide |
|---|---|
| CAS | 1035270-39-3 |
| Cible | FGF Receptor Inhibitors |
| Formule moléculaire | C26H33N5O3 |
| Code produit | Marque | Quantité | Prix | Quantité et disponibilité | |||||
|---|---|---|---|---|---|---|---|---|---|
| Code produit | Marque | Quantité | Prix | Quantité et disponibilité | |||||
|
18717376
|
Tocris Bioscience™
7823/10 |
10 mg |
247.00€
10mg |
Veuillez vous connecter pour pouvoir commander cet article. Besoin d'un compte web? Créer le vôtre dès maintenant! | |||||
|
18718386
|
Tocris Bioscience™
7823/50 |
50 mg |
958.00€
50mg |
Veuillez vous connecter pour pouvoir commander cet article. Besoin d'un compte web? Créer le vôtre dès maintenant! | |||||
Description
AZD 4547 is a potent and selective FGFR1, FGFR3 and FGFR2 tyrosine kinase inhibitor (IC50 values are 0.2 1.8, and 2.5 nM, respectively). It shows selectivity for FGFR across a range of unrelated tyrosine and serine/threonine kinases, including IGFR (>2,900-fold), CDK2 (>50,000-fold), and p38 (>50,000-fold). In vitro, it has antiproliferative effects on tumor cell lines with deregulated FGFR expression. In vivo, AZD 4547 exhibits dose-dependent inhibition of tumor growth in an FGFR-driven human tumor xenograft mice model. It suppresses osteoclastogenesis and tumor-induced osteolysis in an orthotopic breast cancer bone metastasis mouse model. AZD 4547 is orally bioavailable.Spécification
| rel-N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-[(3R,5S)-3,5-dimethyl-1-piperazinyl]benzamide | |
| 1035270-39-3 | |
| FGF Receptor Inhibitors | |
| C26H33N5O3 |
Sécurité et traitement
Recommended Storage : Store the unopened product at -20 to -70 °C. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Do not use past expiration date.